Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2007 2
2008 2
2009 1
2010 1
2011 1
2012 2
2013 2
2014 8
2015 3
2016 2
2017 1
2018 2
2019 1
2020 2
2021 3
2022 6
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Recurrent Platinum-Resistant Primary Peritoneal Carcinoma"
Page 1
Bevacizumab in recurrent ovarian cancer.
Sait Bakir M, Birge O, Karadag C, Ilhan Y, Aykut Tuncer H, Sezgin Göksu S, Simsek T. Sait Bakir M, et al. J BUON. 2021 Jul-Aug;26(4):1271-1278. J BUON. 2021. PMID: 34564981 Free article.
PURPOSE: The cost-effectiveness of bevacizumab has been the subject of debate, and we aimed to present our own retrospective data on its effect on survival in recurrent epithelial ovarian cancer. METHODS: Patients with recurrent ovarian, tubal and primary …
PURPOSE: The cost-effectiveness of bevacizumab has been the subject of debate, and we aimed to present our own retrospective data on its eff …
A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer.
Holloway RW, Thaker P, Mendivil AA, Ahmad S, Al-Niaimi AN, Barter J, Beck T, Chambers SK, Coleman RL, Crafton SM, Crane E, Ramez E, Ghamande S, Graybill W, Herzog T, Indermaur MD, John VS, Landrum L, Lim PC, Lucci JA, McHale M, Monk BJ, Moore KN, Morris R, O'Malley DM, Reid TJ, Richardson D, Rose PG, Scalici JM, Silasi DA, Tewari K, Wang EW. Holloway RW, et al. Int J Gynecol Cancer. 2023 Sep 4;33(9):1458-1463. doi: 10.1136/ijgc-2023-004812. Int J Gynecol Cancer. 2023. PMID: 37666539 Clinical Trial.
Olvimulogene nanivacirepvec (Olvi-Vec), with its strong immune modulating effect on the tumor microenvironment, may provide re-sensitization to platinum and clinically reverse platinum resistance or refractoriness in platinum-resistant/refractory ovarian cancer. …
Olvimulogene nanivacirepvec (Olvi-Vec), with its strong immune modulating effect on the tumor microenvironment, may provide re-sensitization …
Gemcitabine reverses platinum resistance in platinum-resistant ovarian and peritoneal carcinoma.
Rose PG. Rose PG. Int J Gynecol Cancer. 2005 May-Jun;15 Suppl 1:18-22. doi: 10.1111/j.1525-1438.2005.15357.x. Int J Gynecol Cancer. 2005. PMID: 15839954 Free article. Review.
Inhibition of specific exonucleases, such as excision repair cross-complementation group 1 (ERCC1), is integral to the platinum-gemcitabine synergy. In platinum-sensitive recurrent ovarian cancer patients (defined as those patients whose cancer recurs after > 6 months f …
Inhibition of specific exonucleases, such as excision repair cross-complementation group 1 (ERCC1), is integral to the platinum-gemcitabine …
Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer.
Fu S, Corr BR, Culm-Merdek K, Mockbee C, Youssoufian H, Stagg R, Naumann RW, Wenham RM, Rosengarten RD, Benjamin L, Hamilton EP, Moore KN. Fu S, et al. J Clin Oncol. 2022 Aug 10;40(23):2568-2577. doi: 10.1200/JCO.21.01801. Epub 2022 Apr 19. J Clin Oncol. 2022. PMID: 35439029 Free PMC article. Clinical Trial.
PURPOSE: This phase Ib study evaluated the safety and efficacy of paclitaxel plus navicixizumab, a bispecific antiangiogenic antibody to vascular endothelial growth factor and delta-like ligand 4, against platinum-resistant ovarian cancer. PATIENTS AND METHODS: This …
PURPOSE: This phase Ib study evaluated the safety and efficacy of paclitaxel plus navicixizumab, a bispecific antiangiogenic antibody to vas …
Real-world study of bevacizumab treatment in patients with ovarian cancer: a Chinese single-institution study of 155 patients.
Zhang N, Zheng H, Gao Y, Shu T, Wang H. Zhang N, et al. BMC Womens Health. 2023 Apr 13;23(1):178. doi: 10.1186/s12905-023-02329-9. BMC Womens Health. 2023. PMID: 37055754 Free PMC article. Review.
METHODS: We reviewed the clinicopathological data of patients with histologically confirmed epithelial ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma, who were diagnosed and treated at the Department of Gynecologic Oncology of Peking Uni …
METHODS: We reviewed the clinicopathological data of patients with histologically confirmed epithelial ovarian cancer, fallopian tube cancer …
Efficacy and Safety of Platinum Rechallenge in Patients With Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer: A Multicenter Retrospective Study.
Tatsuki S, Shoji T, Abe M, Tomabechi H, Takatori E, Kaido Y, Nagasawa T, Kagabu M, Aida T, Baba T. Tatsuki S, et al. Anticancer Res. 2022 Sep;42(9):4603-4610. doi: 10.21873/anticanres.15964. Anticancer Res. 2022. PMID: 36039449
PATIENTS AND METHODS: The study included 49 patients who received platinum rechallenge therapy for ovarian, fallopian tube or primary peritoneal cancer who were once diagnosed with platinum-resistant recurrence between January 2010 and March 202 …
PATIENTS AND METHODS: The study included 49 patients who received platinum rechallenge therapy for ovarian, fallopian tube or primary …
A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Dizon DS, Blessing JA, Penson RT, Drake RD, Walker JL, Johnston CM, Disilvestro PA, Fader AN. Dizon DS, et al. Gynecol Oncol. 2012 May;125(2):367-71. doi: 10.1016/j.ygyno.2012.02.019. Epub 2012 Feb 21. Gynecol Oncol. 2012. PMID: 22366594 Free PMC article. Clinical Trial.
BACKGROUND: Patients with recurrent ovarian cancer have limited options, especially in the context of relapse less than six months from primary platinum-based therapy. ...CONCLUSIONS: The addition of belinostat to carboplatin had little activity in a population with …
BACKGROUND: Patients with recurrent ovarian cancer have limited options, especially in the context of relapse less than six months fr …
Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer.
Bogani G, Coleman RL, Vergote I, van Gorp T, Ray-Coquard I, Oaknin A, Matulonis U, O'Malley D, Raspagliesi F, Scambia G, Monk BJ. Bogani G, et al. Int J Gynecol Cancer. 2024 Apr 1;34(4):469-477. doi: 10.1136/ijgc-2023-004924. Int J Gynecol Cancer. 2024. PMID: 38101816 Review.
In 2017, a phase I expansion study reported the first experience of MIRV in FRalpha-positive platinum-resistant ovarian cancer with promising results. However, the phase III FORWARD I study failed to demonstrate a significant benefit of MIRV in FRalpha-positive tumo …
In 2017, a phase I expansion study reported the first experience of MIRV in FRalpha-positive platinum-resistant ovarian cancer …
Effectiveness of oral etoposide in recurrent or refractory epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer.
Kongsawatvorakul C, Charakorn C, Chittithaworn S, Lertkhachonsuk AA. Kongsawatvorakul C, et al. J Obstet Gynaecol. 2022 Aug;42(6):2331-2335. doi: 10.1080/01443615.2022.2049724. Epub 2022 Apr 26. J Obstet Gynaecol. 2022. PMID: 35470751
The aim of treatment in recurrent or refractory epithelial ovarian cancer is palliation. In a patient with platinum-resistant status, several chemotherapy regimens have been reported with similar response rates. ...This retrospective study was conducted to ev …
The aim of treatment in recurrent or refractory epithelial ovarian cancer is palliation. In a patient with platinum-resista …
A phase IA dose-escalation study of PHI-101, a new checkpoint kinase 2 inhibitor, for platinum-resistant recurrent ovarian cancer.
Park SJ, Chang SJ, Suh DH, Kong TW, Song H, Kim TH, Kim JW, Kim HS, Lee SJ. Park SJ, et al. BMC Cancer. 2022 Jan 3;22(1):28. doi: 10.1186/s12885-021-09138-z. BMC Cancer. 2022. PMID: 34980026 Free PMC article. Clinical Trial.
Furthermore, the in vivo study suggests the synergistic effect of PHI-101 through combination with PARP inhibitors for ovarian cancer treatment. The primary objective of this study is to evaluate the safety and tolerability of PHI-101 in platinum-resistant …
Furthermore, the in vivo study suggests the synergistic effect of PHI-101 through combination with PARP inhibitors for ovarian cancer treatm …
42 results